| Literature DB >> 32257924 |
Sungjin Park1,2, Minhee Kim1,2, Youngeun Hong1,2, Hyunji Lee1,2, Quangdon Tran1,2, Chaeyeong Kim1,2, So Hee Kwon3, Jisoo Park1,2,4, Jongsun Park1,2, Seon-Hwan Kim5.
Abstract
Lung cancer is the most common cause of cancer-associated death worldwide. Most patients with non-small cell lung cancer die within several years of the initial diagnosis, and new therapies are desperately needed. Transmembrane protein (TMEM) 39AS41, a synthetic peptide, was generated from the protein kinase B substrate motif 34GLRNRNGSAIGLPVP48 found in the human TMEM39A protein. Myristic acid was conjugated to the N-terminus of the peptide to confer cell permeability. In this study, we found that in vitro TMEM39AS41 peptide led to cell death via inhibition of inflammation/autophagy pathways in KRAS-mutated cell and tissues. In addition, TMEM39A, at a dose of 30 mg/kg, significantly suppressed tumor growth in KRASLA1 non-small cell lung cancer mice. These results suggest that the TMEM39AS41 peptide could have therapeutic potential for lung cancer. © Korean Society of Toxicology 2020.Entities:
Keywords: Cell-penetrating peptide; Lung cancer; Myristic acid; Peptide drug; TMEM39A
Year: 2020 PMID: 32257924 PMCID: PMC7099121 DOI: 10.1007/s43188-020-00038-1
Source DB: PubMed Journal: Toxicol Res ISSN: 1976-8257